This content is protected against AI scraping.
The enactment of Section 781 of the 2026 Continuing Appropriations Act materially redefines “hemp,” effectively closing the “loophole” created by the 2018 Farm Bill that allowed for a $28.4 billion intoxicating hemp market. Under the new federal standard, hemp is limited to a total THC concentration (including THCA and Delta-8) of 0.3% on a dry weight basis, with finished products capped at a mere 0.4 milligrams of total THC per container. Furthermore, the Act expressly prohibits cannabinoids synthesized outside the plant or those not naturally occurring. This shift is estimated to render 95% of current hemp-derived products—including many non-intoxicating CBD formulations—federally unlawful and classified as “marijuana” under the Controlled Substances Act as of November 12, 2026.
The legislative change has triggered immediate economic and legal disruption, threatening approximately 300,000 jobs and $1.5 billion in state tax revenue. While enforcement is deferred for a 365-day transition period, the industry faces significant uncertainty as the FDA prepares to define “containers” and list restricted cannabinoids. In response, several legislative efforts have emerged: the American Hemp Protection Act seeks a full repeal, the Hemp Planting Predictability Act proposes a three-year delay to allow for a permanent framework, and the Cannabinoid Safety and Regulation Act (CSRA) suggests a comprehensive federal regulatory system with higher THC limits and safety standards. Read the full story.
Referenced article written by Edgar Asebey and Guilherme Ferrari Faviero. Published on March 3, 2026 by Frier Levitt.
